Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

To the Editor: In the IMpassion130 trial, Schmid et al. (Nov. 29 issue) 1 found that combination therapy with atezolizumab plus nanoparticle albumin-bound (nab)–paclitaxel led to longer progression-free survival than placebo plus nab-paclitaxel among patients with metastatic triple-negative breast cancer. The effect was observed both in the intention-to-treat population and in the population of patients with tumors that were positive for programmed death ligand 1 (PD-L1). In this trial, the BRCA mutation profile of the patients was not reported in the published data. It has been widely reported that germline mutations in BRCA1 or BRCA2 cause DNA-repair defects and genomic instability. 2 . . .